miR-637、miR-223-3p、PARP14在甲状腺癌中的表达及与临床特征的相关性
Expressions and clinical correlation of miR-637,miR-223-3p and PARP14 in thyroid cancer
冯玉俊 1王林娜 2赵正历 3刘海楠4
作者信息
- 1. 053000 衡水,衡水市人民医院核医学科
- 2. 053000 衡水,衡水市人民医院病理科
- 3. 053000 衡水,衡水市人民医院内分泌科
- 4. 050081 石家庄,河北省残疾人康复中心孤独症康复科
- 折叠
摘要
目的 探究miR-637、miR-223-3p、多聚(腺苷二磷酸核糖)聚合酶14(PARP14)在甲状腺癌中的表达及与临床特征相关性.方法 选取2018年5月至2020年5月衡水市人民医院73例甲状腺癌患者.采用PCR法检测患者癌组织及癌旁组织miR-637、miR-223-3p、PARP14表达;所有患者随访3年,根据生存情况将其分为死亡组及生存组,分析患者癌组织miR-637、miR-223-3p、PARP14表达与预后的关系及对预后的预测价值.结果 甲状腺癌组织miR-637 mRNA表达量低于癌旁组织,miR-223-3p、PARP14mRNA表达量高于癌旁组织(P＜0.05).miR-637 mRNA在临床分期Ⅲ～Ⅳ期、包膜浸润及淋巴结转移患者中均为低表达(P＜0.05),PARP14mRNA在临床分期Ⅲ-Ⅳ期、肿瘤直径≥2 cm、包膜浸润及淋巴结转移患者中均为高表达(P＜0.05),miR-223-3p mRNA在肿瘤直径≥2 cm、包膜浸润及淋巴结转移患者中均为高表达(P＜0.05).死亡组癌组织miR-637 mRNA表达量低于生存组,miR-223-3p、PARP14表达mRNA表达量高于生存组(P＜0.05).多因素Cox回归显示,癌组织miR-637 mRNA表达量升高为影响甲状腺癌患者预后的危险因素,miR-223-3p、PARP14mRNA表达量升高为保护因素(P＜0.05).癌组织miR-637、miR-223-3p、PARP14表达联合检测预测甲状腺癌患者预后的AUC值大于各指标单独检测(P＜0.05).癌组织miR-637低表达患者的累积生存率低于高表达患者(P＜0.05);癌组织miR-223-3p、PARP14高表达患者的累积生存率低于低表达患者(P＜0.05).结论 甲状腺患者癌组织miR-637、miR-223-3p、PARP14 mRNA呈异常表达现象,上述指标mRNA表达量与临床分期、肿瘤直径、淋巴结转移等临床特征及预后有关,且miR-637、miR-223-3p、PARP14联合可用于评估患者预后.
Abstract
Objective To investigate the expressions of miR-637,miR-223-3p and PARP14 in thyroid cancer and their corre-lation with clinical features.Methods This study selected 73 patients with thyroid cancer from May 2018 to May 2020 at Hengshui People's Hospital.The expressions of miR-637,miR-223-3p and PARP14 in cancerous and adjacent non-cancerous tissues were de-tected by PCR.All patients were followed up for 3 years and divided into death and survival groups based on their survival status.The relationship between expressions of miR-637,miR-223-3p and PARP14 in cancerous tissues and the prognosis,as well as their predic-tive value for prognosis,was analyzed.Results The expressions of miR-637 in thyroid cancerous tissues was lower than that in adjacent non-cancerous tissues,while the expressions of miR-223-3p and PARP14 were higher(P＜0.05).The expressions of miR-637 mRNA was lower in patients with clinical stage Ⅲ to Ⅳ,capsular invasion and lymph node metastasis(P＜0.05).The expressions of PARP14 was higher in patients with clinical stage Ⅲ to Ⅳ,tumor diameter ≥2cm,capsular invasion and lymph node metastasis(P＜0.05).The ex-pressions of miR-223-3p was higher in patients with tumor diameter ≥2cm,capsular invasion and lymph node metastasis(P＜0.05).The expressions of miR-637 in the cancerous tissues of the death group was lower than that of the survival group,while the expressions of miR-223-3p and PARP14 were higher(P＜0.05).Multivariate Cox regression showed that an increased expression of miR-637 in cancerous tissues was a risk factor for the prognosis of patients with thyroid cancer,while the increased expressions of miR-223-3p and PARP14 were protective factors(P＜0.05).The combined detection of miR-637,miR-223-3p and PARP14 expression in cancerous tis-sues had a greater Area Under Curve(AUC)value in predicting the prognosis of patients with thyroid cancer than the individual detec-tion of each marker(P＜0.05).Patients with low miR-637 expressions in cancerous tissues had a lower cumulative survival rate than those of patients with high expressions(P＜0.05);patients with high expressions of miR-223-3p and PARP14 in cancerous tissues had a lower cumulative survival rate than those of patients with low expressions(P＜0.05).Conclusion Abnormal expressions of miR-637,miR-223-3p and PARP14 were observed in the cancerous tissues of patients with thyroid cancer.The expressions of these mark-ers correlated with clinical stages,tumor diameter,lymph node metastasis,and other clinical features and prognosis.Furthermore,the combination of miR-637,miR-223-3p and PARP14 can be used to assess patient prognosis.
关键词
甲状腺/微小RNA-637/微小RNA-223-3p/多聚(腺苷二磷酸核糖)聚合酶14/临床特征/预后Key words
thyroid/microRNA-637/microRNA-223-3p/poly(adenosine diphosphate ribose)polymerase 14/clinical fea-tures/prognosis引用本文复制引用
基金项目
河北省医学科学研究课题(20220471)
出版年
2024
NETL
NSTL
万方数据